Cargando…

Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation

INTRODUCTION: Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0–3.0 over 65%–7...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera-Caravaca, José Miguel, Marín, Francisco, Esteve-Pastor, María Asunción, Gálvez, Josefa, Lip, Gregory Y.H., Vicente, Vicente, Roldán, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924708/
https://www.ncbi.nlm.nih.gov/pubmed/31843852
http://dx.doi.org/10.1136/bmjopen-2019-033712
_version_ 1783481770416537600
author Rivera-Caravaca, José Miguel
Marín, Francisco
Esteve-Pastor, María Asunción
Gálvez, Josefa
Lip, Gregory Y.H.
Vicente, Vicente
Roldán, Vanessa
author_facet Rivera-Caravaca, José Miguel
Marín, Francisco
Esteve-Pastor, María Asunción
Gálvez, Josefa
Lip, Gregory Y.H.
Vicente, Vicente
Roldán, Vanessa
author_sort Rivera-Caravaca, José Miguel
collection PubMed
description INTRODUCTION: Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0–3.0 over 65%–70%. Unfortunately, the difficulties of maintaining an optimal level of anticoagulation and the complications of VKAs (particularly haemorrhagic ones), frequently lead to cessation of this therapy, which has been associated with higher risk of adverse events (AEs), including ischaemic stroke. Our aims are as follows: (1) to evaluate the quality of oral anticoagulation with VKAs, the prevalence of poor quality of anticoagulation, and to identify factors predisposing to poor quality anticoagulation; and (2) to identify patients who will stop OAC and to investigate what factors influence the decision of OAC withdrawal. METHODS AND ANALYSIS: Prospective observational cohort study including outpatients newly diagnosed with AF and naïve for OACs from July 2016 to June 2018 in an anticoagulation clinic. Patients with prosthetic heart valves, rheumatic mitral valves or valvular AF will be excluded. Follow-up will extend for up to 3 years. During this period, the INR results and changes in the anticoagulant therapy will be recorded, as well as all AEs, or any other information that would be relevant to the proper conduct of research. ETHICS AND DISSEMINATION: All patients were informed about the nature and purpose of the study, and the protocol was approved by the Ethics Committee of Hospital General Universitario Morales Meseguer (reference: EST:20/16). This is an observational study focusing on ‘real life’ practice and therefore all treatments and follow-up will be performed in accordance to the routine clinical practice with no specific interventions or visits. The results of our study will be disseminated by presentations at national and international meetings, and publications in peer-reviewed journals.
format Online
Article
Text
id pubmed-6924708
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-69247082020-01-02 Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation Rivera-Caravaca, José Miguel Marín, Francisco Esteve-Pastor, María Asunción Gálvez, Josefa Lip, Gregory Y.H. Vicente, Vicente Roldán, Vanessa BMJ Open Cardiovascular Medicine INTRODUCTION: Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0–3.0 over 65%–70%. Unfortunately, the difficulties of maintaining an optimal level of anticoagulation and the complications of VKAs (particularly haemorrhagic ones), frequently lead to cessation of this therapy, which has been associated with higher risk of adverse events (AEs), including ischaemic stroke. Our aims are as follows: (1) to evaluate the quality of oral anticoagulation with VKAs, the prevalence of poor quality of anticoagulation, and to identify factors predisposing to poor quality anticoagulation; and (2) to identify patients who will stop OAC and to investigate what factors influence the decision of OAC withdrawal. METHODS AND ANALYSIS: Prospective observational cohort study including outpatients newly diagnosed with AF and naïve for OACs from July 2016 to June 2018 in an anticoagulation clinic. Patients with prosthetic heart valves, rheumatic mitral valves or valvular AF will be excluded. Follow-up will extend for up to 3 years. During this period, the INR results and changes in the anticoagulant therapy will be recorded, as well as all AEs, or any other information that would be relevant to the proper conduct of research. ETHICS AND DISSEMINATION: All patients were informed about the nature and purpose of the study, and the protocol was approved by the Ethics Committee of Hospital General Universitario Morales Meseguer (reference: EST:20/16). This is an observational study focusing on ‘real life’ practice and therefore all treatments and follow-up will be performed in accordance to the routine clinical practice with no specific interventions or visits. The results of our study will be disseminated by presentations at national and international meetings, and publications in peer-reviewed journals. BMJ Publishing Group 2019-12-12 /pmc/articles/PMC6924708/ /pubmed/31843852 http://dx.doi.org/10.1136/bmjopen-2019-033712 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Rivera-Caravaca, José Miguel
Marín, Francisco
Esteve-Pastor, María Asunción
Gálvez, Josefa
Lip, Gregory Y.H.
Vicente, Vicente
Roldán, Vanessa
Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title_full Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title_fullStr Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title_full_unstemmed Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title_short Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
title_sort murcia atrial fibrillation project ii: protocol for a prospective observational study in patients with atrial fibrillation
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924708/
https://www.ncbi.nlm.nih.gov/pubmed/31843852
http://dx.doi.org/10.1136/bmjopen-2019-033712
work_keys_str_mv AT riveracaravacajosemiguel murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT marinfrancisco murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT estevepastormariaasuncion murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT galvezjosefa murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT lipgregoryyh murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT vicentevicente murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation
AT roldanvanessa murciaatrialfibrillationprojectiiprotocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation